Compounding • FDA • Drug Safety • Recalls • Pharmacy Operations

FDA Posts a Multi-Product Compounding Recall for Victory Medical Center Pharmacy

FDA posted and classified an ongoing voluntary recall involving Victory Medical Center Pharmacy on October 30. The Austin pharmacy initiated the action October 19. FDA identifies 42 Class II product entries and distribution in Colorado, Florida, and Texas, with lack of processing controls as the stated reason. The records include compounded semaglutide and tirzepatide combinations, peptides, and vitamin preparations. Pharmacies and receiving practices should match the specific product and lot records before acting, rather than treating every preparation from the facility as recalled.

By Toby C. “Chad” Frost • November 2, 2026
2 min read

What FDA posted

FDA’s recall event 100168 identifies Victory Medical Center Pharmacy in Austin, Texas, an October 19, 2026 voluntary initiation, October 30 internet posting and classification, and an ongoing status. The event lists 5,918 vials distributed in Colorado, Florida, and Texas.1

Its 42 Class II entries cite lack of processing controls and include semaglutide and tirzepatide combinations, peptides, and vitamin preparations. Product-specific records identify affected lots and expiration dates. Some listed expirations extend beyond November 2. These entries concern particular preparations and lots, rather than every product from the pharmacy.1

Turn the records into a documented response

Chad’s analysis: Start by identifying whether the practice or pharmacy received any listed preparation. Reconcile the supplier, product name, strength, vial size, lot, and expiration against the source records. Preserve a copy of the notice used for that review so later changes can be tracked. A matching ingredient name alone should not close the investigation.

Chad’s analysis: Assign responsibility for holding any matching stock and obtaining the firm’s current disposition instructions. Reconcile amounts received, used, remaining, and returned or otherwise handled. Where a match is confirmed, coordinate the response with the prescribing practice and document the relevant patient or administration records. Keep unresolved questions visible rather than assuming that an expired vial needs no follow-up. The incident review should also examine supplier qualification and how recall information reaches staff who receive, store, prepare, or administer compounded products. Record whom the team contacted, what instructions were received, and who confirmed completion. A clear disposition trail supports later review if a supplier or regulator asks questions.

Source notes

  1. U.S. Food & Drug Admin., Enforcement Report, Recall Event 100168, Victory Medical Center Pharmacy, Event Details & Product Records D-0114-2027–D-0155-2027 (initiated Oct. 19, 2026; posted and classified Oct. 30, 2026) (last visited Nov. 2, 2026).